DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
MLN1117 is an investigational drug.
There have been 8 clinical trials for MLN1117. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2016.
The most common disease conditions in clinical trials are Neoplasms, Endometrial Neoplasms, and Carcinoma, Renal Cell. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., Avera McKennan Hospital & University Health Center, and European Network of Translational Research in Ovarian Cancer - EUTROC.
There are four US patents protecting this investigational drug and sixty-three international patents.
Recent Clinical Trials for MLN1117
|Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors||Avera McKennan Hospital & University Health Center||Phase 1|
|MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma||Millennium Pharmaceuticals, Inc.||Phase 2|
|Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer||European Network of Individualized Treatment in Endometrial Cancer - ENITEC||Phase 2|
Top disease conditions for MLN1117
Top clinical trial sponsors for MLN1117
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|MLN1117||Start Trial||Heterocyclic compounds and uses thereof||INTELLIKINE, INC. (La Jolla, CA)||Start Trial|
|MLN1117||Start Trial||Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof||Intellikine LLC (La Jolla, CA)||Start Trial|
|MLN1117||Start Trial||Kinase inhibitor polymorphs||Intellikine LLC (La Jolla, CA) Sigma-Aldrich Company Limited (GB)||Start Trial|
|MLN1117||Start Trial||Combination of kinase inhibitors and uses thereof||Intellikine LLC (La Jolla, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|